Eli Lilly and Co. is looking to Cambridge startup Insilico Medicine to assist it with AI-driven drug discovery work.

Insilico announced a research and licensing collaboration with the Indianapolis pharma giant on Monday. The deal provides Insilico with potentially more than $100 million through an upfront payment, milestone payments, and tiered royalties on net sales upon commercialization of any drug products. In turn, Insilico brings to the table its generative Al software and automation platform called Pharma.AI.

Stream NBC10 Boston news for free, 24/7, wherever you are. WATCH HERE

More on this story from Boston Business Journal

See Full Page